A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Meningitis still affects more than 2.5 million people globally each year
The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections
Approval strengthens the company’s growing international anti-infective portfolio
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
The product is expected to be launched by Q4 FY23.
Subscribe To Our Newsletter & Stay Updated
